These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23527043)

  • 1. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.
    Huang CF; Dai CY; Yeh ML; Huang JF; Huang CI; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chuang WL; Lin YC; Yu ML
    PLoS One; 2013; 8(3):e58882. PubMed ID: 23527043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Huang CF; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chen KC; Chuang WL; Kuo HT; Dai CY; Yu ML
    J Hepatol; 2012 Jan; 56(1):34-40. PubMed ID: 21703176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Huang CF; Yeh ML; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Hsi E; Juo SH; Dai CY; Chuang WL; Yu ML
    Antiviral Res; 2012 Feb; 93(2):239-244. PubMed ID: 22193282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
    Yu ML; Liu CH; Huang CF; Tseng TC; Huang JF; Dai CY; Lin ZY; Chen SC; Wang LY; Juo SH; Chuang WL; Kao JH
    PLoS One; 2012; 7(12):e52048. PubMed ID: 23284866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.
    Wong GL; Chan HL; Tse CH; Chan PO; Cheng JC; Cheng JS; Lau SH; Lee EK; Ma JM; Chan AW; Choi PC; Wong VW
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1040-8. PubMed ID: 25639146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.
    Papastergiou V; Skorda L; Lisgos P; Stampori M; Ntetskas G; Papakonstantinou L; Prodromidou K; Karatapanis S
    J Clin Gastroenterol; 2014 Feb; 48(2):160-5. PubMed ID: 24100748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
    J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
    Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.
    Derbala M; Rizk NM; Al-Kaabi S; John A; Sharma M; El-dweik N; Yakoob R; Pasic F; Almohanadi M; Alejji K; Abdelmola A; Butt M
    Virology; 2013 Sep; 444(1-2):292-300. PubMed ID: 23866096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.